Boxer Capital
Latest statistics and disclosures from Boxer Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SWTX, CYTK, RVMD, TYRA, APLS, and represent 32.63% of Boxer Capital's stock portfolio.
- Added to shares of these 10 stocks: FATE (+$57M), NKTX (+$45M), VKTX (+$25M), KURA (+$21M), ALLO (+$17M), RNA (+$16M), SANA (+$16M), PSTX (+$14M), ENGN (+$12M), THRD (+$12M).
- Started 13 new stock positions in LABD, ALLO, IPSC, ENGN, SANA, JSPR, ATRA, AMLX, VKTX, KURA. Boundless Bio, ABSI, PSTX.
- Reduced shares in these 10 stocks: Mirati Therapeutics (-$188M), , Karuna Therapeutics Ord (-$79M), ARGX (-$24M), IOVA (-$9.6M), IMVT (-$5.7M), KOD, Rain Therapeutics, KALV, BCEL.
- Sold out of its positions in BCEL, ImmunoGen, Karuna Therapeutics Ord, KOD, Mirati Therapeutics, Rain Therapeutics.
- Boxer Capital was a net seller of stock by $-112M.
- Boxer Capital has $2.0B in assets under management (AUM), dropping by 0.92%.
- Central Index Key (CIK): 0001465837
Tip: Access up to 7 years of quarterly data
Positions held by Boxer Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Boxer Capital
Boxer Capital holds 59 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Springworks Therapeutics (SWTX) | 8.3 | $168M | 3.4M | 49.22 |
|
|
| Cytokinetics Com New (CYTK) | 7.3 | $147M | 2.1M | 70.11 |
|
|
| Revolution Medicines (RVMD) | 6.8 | $138M | 4.3M | 32.23 |
|
|
| Tyra Biosciences (TYRA) | 5.2 | $106M | 6.4M | 16.40 |
|
|
| Apellis Pharmaceuticals (APLS) | 5.0 | $102M | 1.7M | 58.78 |
|
|
| Ideaya Biosciences (IDYA) | 4.8 | $97M | 2.2M | 43.88 |
|
|
| Merus N V (MRUS) | 4.2 | $86M | 1.9M | 45.03 |
|
|
| Sarepta Therapeutics (SRPT) | 4.2 | $84M | 650k | 129.46 |
|
|
| Nuvalent Inc-a (NUVL) | 4.2 | $84M | 1.1M | 75.09 |
|
|
| BeiGene Sponsored Adr (BGNE) | 3.9 | $78M | 500k | 156.39 |
|
|
| Tango Therapeutics (TNGX) | 3.2 | $65M | 8.2M | 7.94 |
|
|
| Nkarta (NKTX) | 3.0 | $61M | +289% | 5.6M | 10.81 |
|
| Fate Therapeutics (FATE) | 3.0 | $60M | +1543% | 8.2M | 7.34 |
|
| Avidity Biosciences Ord (RNA) | 2.2 | $44M | +54% | 1.7M | 25.52 |
|
| Akero Therapeutics (AKRO) | 2.1 | $42M | 1.7M | 25.26 |
|
|
| Rocket Pharmaceuticals (RCKT) | 2.0 | $40M | 1.5M | 26.94 |
|
|
| Argenx SE Sponsored Adr (ARGX) | 1.9 | $39M | -37% | 100k | 393.72 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.7 | $34M | 600k | 56.09 |
|
|
| Axsome Therapeutics (AXSM) | 1.6 | $32M | 400k | 79.80 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 1.5 | $30M | 1.6M | 18.88 |
|
|
| Anaptysbio Inc Common (ANAB) | 1.4 | $29M | 1.3M | 22.52 |
|
|
| Immunovant (IMVT) | 1.3 | $27M | -17% | 825k | 32.31 |
|
| Xenon Pharmaceuticals (XENE) | 1.3 | $26M | 600k | 43.05 |
|
|
| Arvinas Ord (ARVN) | 1.2 | $25M | 609k | 41.28 |
|
|
| Iteos Therapeutics (ITOS) | 1.2 | $25M | 1.8M | 13.64 |
|
|
| Viking Therapeutics (VKTX) | 1.2 | $25M | NEW | 300k | 82.00 |
|
| Oric Pharmaceuticals (ORIC) | 1.2 | $24M | 1.7M | 13.75 |
|
|
| Kura Oncology (KURA) | 1.1 | $21M | NEW | 1.0M | 21.33 |
|
| Geron Corporation (GERN) | 1.0 | $20M | +100% | 6.0M | 3.30 |
|
| Day One Biopharmaceuticals I (DAWN) | 1.0 | $20M | 1.2M | 16.52 |
|
|
| Third Harmonic Bio (THRD) | 0.9 | $19M | +166% | 2.0M | 9.44 |
|
| Kalvista Pharmaceuticals (KALV) | 0.9 | $19M | -3% | 1.6M | 11.86 |
|
| Allogene Therapeutics (ALLO) | 0.8 | $17M | NEW | 3.9M | 4.47 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.8 | $17M | 400k | 42.86 |
|
|
| Prothena Corp SHS (PRTA) | 0.8 | $17M | +3% | 690k | 24.77 |
|
| Sana Biotechnology (SANA) | 0.8 | $16M | NEW | 1.5M | 10.00 |
|
| Relay Therapeutics (RLAY) | 0.7 | $15M | 1.8M | 8.30 |
|
|
| Poseida Therapeutics I (PSTX) | 0.7 | $14M | NEW | 4.5M | 3.19 |
|
| Engene Holdings (ENGN) | 0.6 | $12M | NEW | 728k | 16.95 |
|
| Prelude Therapeutics (PRLD) | 0.6 | $12M | 2.6M | 4.74 |
|
|
| Enliven Therapeutics (ELVN) | 0.6 | $12M | +3% | 671k | 17.59 |
|
| Iovance Biotherapeutics (IOVA) | 0.5 | $11M | -46% | 750k | 14.82 |
|
| Jasper Therapeutics Com New (JSPR) | 0.5 | $10M | NEW | 350k | 29.36 |
|
| Boundless Bio | 0.5 | $10M | NEW | 711k | 14.25 |
|
| Spyre Therapeutics Com New (SYRE) | 0.5 | $9.5M | 250k | 37.93 |
|
|
| Century Therapeutics (IPSC) | 0.4 | $7.3M | NEW | 1.8M | 4.18 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.4 | $7.1M | 450k | 15.76 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 0.2 | $4.3M | NEW | 1.5M | 2.84 |
|
| Absci Corp (ABSI) | 0.2 | $4.0M | NEW | 700k | 5.68 |
|
| Atara Biotherapeutics (ATRA) | 0.1 | $2.9M | NEW | 4.2M | 0.69 |
|
| Black Diamond Therapeutics (BDTX) | 0.1 | $2.6M | 506k | 5.07 |
|
|
| Direxion SHS ETF TR Daily S&p Biotec (LABD) | 0.1 | $2.6M | NEW | 350k | 7.29 |
|
| Bioatla (BCAB) | 0.1 | $2.4M | 686k | 3.44 |
|
|
| Health Sciences Acq Corp 2 (OBIO) | 0.1 | $1.3M | 238k | 5.27 |
|
|
| Protara Therapeutics Com Stk (TARA) | 0.0 | $839k | 209k | 4.01 |
|
|
| Milestone Pharmaceuticals (MIST) | 0.0 | $553k | 309k | 1.79 |
|
|
| DBV Technologies S A Sponsored Adr (DBVT) | 0.0 | $375k | 500k | 0.75 |
|
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $81k | 267k | 0.30 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $2.2k | 67k | 0.03 |
|
Past Filings by Boxer Capital
SEC 13F filings are viewable for Boxer Capital going back to 2015
- Boxer Capital 2024 Q1 filed May 15, 2024
- Boxer Capital 2023 Q4 filed Feb. 14, 2024
- Boxer Capital 2023 Q3 filed Nov. 14, 2023
- Boxer Capital 2023 Q2 filed Aug. 14, 2023
- Boxer Capital 2023 Q1 filed May 15, 2023
- Boxer Capital 2022 Q4 filed Feb. 14, 2023
- Boxer Capital 2022 Q3 filed Nov. 14, 2022
- Boxer Capital 2022 Q2 filed Aug. 15, 2022
- Boxer Capital 2022 Q1 filed May 16, 2022
- Boxer Capital 2021 Q4 filed Feb. 14, 2022
- Boxer Capital 2021 Q3 filed Nov. 15, 2021
- Boxer Capital 2021 Q2 filed Aug. 16, 2021
- Boxer Capital 2021 Q1 filed May 17, 2021
- Boxer Capital 2020 Q4 filed Feb. 16, 2021
- Boxer Capital 2020 Q3 restated filed Nov. 17, 2020
- Boxer Capital 2020 Q3 filed Nov. 16, 2020